ArrayExpress Uploaderarrayexpress_sidhuman34nonrespondermalelesional59week 1234nonrespondermalenon lesional59week 1234nonrespondermalelesional76week 234nonrespondermalenon lesional76week 234nonrespondermalelesional76day 163respondermalelesional16.1week 1263respondermalelesional58week 263respondermalelesional98day 132respondermalelesional25.5week 1232respondermalenon lesional25.5week 1232respondermalelesional43.5week 232respondermalenon lesional43.5week 232respondermalelesional54day 132respondermalenon lesional54day 159respondermalelesional39.5week 1259respondermalenon lesional39.5week 1259respondermalelesional46.5week 259respondermalenon lesional46.5week 259respondermalelesional97day 159respondermalenon lesional97day 132respondermalelesional16week 1232respondermalenon lesional16week 1232respondermalelesional20week 232respondermalenon lesional20week 232respondermalelesional74.5day 132respondermalenon lesional74.5day 118nonrespondermalelesional37week 1218nonrespondermalenon lesional37week 1218nonrespondermalelesional44.5week 218nonrespondermalenon lesional44.5week 218nonrespondermalelesional73.5day 118nonrespondermalenon lesional73.5day 133respondermalelesional0week 1233respondermalenon lesional0week 1233respondermalelesional5.9week 233respondermalenon lesional5.9week 233respondermalelesional66day 133respondermalenon lesional66day 132respondermalelesional27week 1232respondermalenon lesional27week 1232respondermalelesional64.5week 232respondermalenon lesional64.5week 232respondermalelesional84.5day 132respondermalenon lesional84.5day 150responderfemalelesional7week 1250responderfemalenon lesional7week 1269respondermalelesional20week 1269respondermalenon lesional20week 1236responderfemalelesional18week 1236responderfemalenon lesional18week 1242respondermalelesional10week 1242respondermalenon lesional10week 1242respondermalelesional34week 242respondermalenon lesional34week 242respondermalelesional53day 142respondermalenon lesional53day 136responderfemalelesional26week 236responderfemalenon lesional26week 236responderfemalelesional65day 136responderfemalenon lesional65day 169respondermalelesionalNAweek 269respondermalenon lesionalNAweek 269respondermalelesional61day 169respondermalenon lesional61day 159responderfemalelesional6week 1259responderfemalenon lesional6week 1259responderfemalelesional16week 259responderfemalenon lesional16week 259responderfemalelesional56day 159responderfemalenon lesional56day 140responderfemalelesional15week 1240responderfemalenon lesional15week 1240responderfemalelesional40week 240responderfemalenon lesional40week 240responderfemalelesional72day 140responderfemalenon lesional72day 167responderfemalelesional6week 1267responderfemalenon lesional6week 1267responderfemalelesional14week 267responderfemalenon lesional14week 267responderfemalelesional53day 167responderfemalenon lesional53day 150responderfemalelesional21week 250responderfemalenon lesional21week 250responderfemalenon lesional44day 159responderfemalelesional15week 1259responderfemalenon lesional15week 1259responderfemalelesionalNAweek 259responderfemalenon lesionalNAweek 259responderfemalelesional45day 159responderfemalenon lesional45day 148respondermalelesional7week 1248respondermalenon lesional7week 1248respondermalelesional18week 248respondermalenon lesional18week 248respondermalelesional51day 148respondermalenon lesional51day 149responderfemalelesional8week 1249responderfemalenon lesional8week 1249responderfemalelesional24week 249responderfemalenon lesional24week 249responderfemalelesional56day 149responderfemalenon lesional56day 145respondermalelesional8week 1245respondermalenon lesional8week 1245respondermalelesional15week 245respondermalenon lesional15week 245respondermalelesional56day 145respondermalenon lesional56day 1199904After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in SCORAD scores. Clinical...E-GEOD-58558/profile/8773/arrayexpressuploader6109skinDec.12, 2014FalseE-GEOD-58558_A-AFFY-44cyclosporine-in-patients-with-atopic-dermatitis-moCyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathologyJul.10, 2014After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in SCORAD scores. Clinical improvements were associated with significant gene expression changes in lesional but also nonlesional skin, particularly reductions in levels of TH2-, TH22-, and some TH17-related molecules (ie, IL-13, IL-22, CCL17, S100As, and elafin/peptidase inhibitor 3), and modulation of epidermal hyperplasia and differentiation measures. CsA's effects on AD skin pathology were evaluated by using gene expression and immunohistochemistry studies in baseline, week 2, and week 12 lesional and nonlesional biopsy specimens from 19 patients treated with 5 mg/kg/d CsA for 12 weeks.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-58558http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-58558/samples/